Lixte Bio Shares Jump on LB-100 Trial
20 Setembro 2023 - 11:20AM
Dow Jones News
By Dean Seal
Shares of Lixte Biotechnologies jumped after the company said it
will launch a trial to assess whether its drug LB-100 can aid
immunotherapy in the treatment of ovarian clear cell carcinoma.
The stock was up 11% at $1.95 in early trading. Shares have
fallen 62% since the start of the year.
The Pasadena, Calif.-based biotechnology company said the Phase
1b collaborative clinical trial will assess whether adding LB-100
to GSK's programmed death receptor-1 blocking monoclonal antibody,
dostarlimab, can enhance its effectiveness in treating ovarian
clear cell carcinoma.
GSK will provide dostarlimab and financial support for the
clinical trial.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 20, 2023 10:05 ET (14:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024